


Figure S1. Effect of cPLA<sub>2</sub> deficiency on platelet TXA<sub>2</sub> release to a range of agonists. TXA<sub>2</sub> release (measured as TXB<sub>2</sub>) by platelet-rich plasma from healthy volunteer or cPLA<sub>2</sub> $\alpha$ -deficient patients (patient B + patient S) blood in response to stimulation by collagen (0.3-3  $\mu$ g/ml), ADP (5  $\mu$ mol/L), U46619 (10  $\mu$ mol/L) or arachidonic acid (1mmol/L). n=4 (healthy volunteers), n=2 (patient).



**Figure S2. Effect of cPLA<sub>2</sub> inhibition on prostacyclin release by endothelial cells.** Prostacyclin release (measured as 6-keto-PGF<sub>10</sub>) by endothelial cells isolation from healthy volunteer or cPLA<sub>2</sub>α -deficient patient (patient S) blood in response to A23187 stimulation in the presence of increasing concentrations of the cPLA<sub>2</sub> inhibitor, pyrrophenone. n=4 (healthy volunteers), n=1 (patient).